EHC, WFH, EAHAD and NHF publish guidance on COVID-19 vaccines
in people with rare bleeding disorders.

Read the document.
uniQure's gene therapy programme, HOPE-B,
put on hold by US regulatory authorities.

Read the EHC's press release.
Read the latest issue of the EHC New Product Newsletter WFH - EHC - NHF joint statement Global dosing hold in fitusiran trials EHC introduces Russian Friday
Read the latest EHC news in Russian


EHC - European Haemophilia Consortium (EHC)

EHC - The European Haemophilia Consortium (EHC) is an international non-profit organisation that represents 46 national patients’ organisations of people with rare bleeding disorders from 27 Member States of the European Union (EU) and most Member States of the Council of Europe.

The EHC represents approximately 90,000 people diagnosed with a rare bleeding condition such as haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders across Europe. However, it is estimated that many more live with an undiagnosed rare bleeding disorder.

The EHC draws on the knowledge of patients, healthcare professionals, the scientific community, the European institutions and the pharmaceutical industry to share expertise within Europe. The EHC also collaborates closely with other European patient organisations to ensure a strong collective voice for people with rare bleeding disorders.